We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current CRNX market cap is 3.8B. The company's latest EPS is USD -2.3133 and P/E is -17.53.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 346k | 0 | 640k | 399k | 0 |
| Operating Income | -58.98M | -67.86M | -73.53M | -82.78M | -87.8M |
| Net Income | -57.46M | -60.1M | -66.93M | -74.06M | -76.83M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.19M | 71k | 1.08M | 4.74M | 4.01M |
| Operating Income | -53.83M | -74.95M | -107.7M | -168.89M | -227.81M |
| Net Income | -50.42M | -73.81M | -107.64M | -163.92M | -214.53M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 641.54M | 635.35M | 978.15M | 935.54M | 937.37M |
| Total Liabilities | 93.79M | 96.25M | 103.22M | 104.77M | 104.39M |
| Total Equity | 547.75M | 539.11M | 874.93M | 830.76M | 832.98M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 130.38M | 183.45M | 351.02M | 352.18M | 635.35M |
| Total Liabilities | 13.24M | 14.53M | 19.07M | 35.85M | 96.25M |
| Total Equity | 117.14M | 168.92M | 331.94M | 316.33M | 539.11M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -127.79M | -166.31M | -52.86M | -98.47M | -161.3M |
| Investing | -113.11M | -200.41M | 309k | -53.33M | -32.73M |
| Financing | 351.02M | 388.94M | 393.57M | 399.07M | 456.4M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -46.38M | -62.03M | -88.59M | -115.21M | -166.31M |
| Investing | 41.67M | 217k | -56.48M | -173.98M | -200.41M |
| Financing | 67k | 114.57M | 252.68M | 121.96M | 388.94M |
| Market Cap | 3.8B |
| Price to Earnings Ratio | -17.53 |
| Price to Sales Ratio | 936.72 |
| Price to Cash Ratio | 68.51 |
| Price to Book Ratio | 6.98 |
| Dividend Yield | - |
| Shares Outstanding | 92.74M |
| Average Volume (1 week) | 632.81k |
| Average Volume (1 Month) | 731.06k |
| 52 Week Change | 8.87% |
| 52 Week High | 62.53 |
| 52 Week Low | 35.24 |
| Spread (Intraday) | 3.54 (8.13%) |
| Company Name | Crinetics Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.crinetics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
